Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
Zhai, L
Balachandran, A
Larkin, R
Seneviratne, JA
Chung, SA
Lalwani, A
Tsubota, S
Beck, D
Kadomatsu, K
Beckers, A
Durink, K
De Preter, K
Speleman, F
Haber, M
Norris, MD
Swarbrick, A
Cheung, BB
Marshall, GM
Carter, DR
- Publisher:
- MDPI
- Publication Type:
- Journal Article
- Citation:
- Int J Mol Sci, 2023, 24, (21), pp. 15571
- Issue Date:
- 2023-10-25
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Zhai, L | |
dc.contributor.author | Balachandran, A | |
dc.contributor.author | Larkin, R | |
dc.contributor.author | Seneviratne, JA | |
dc.contributor.author | Chung, SA | |
dc.contributor.author | Lalwani, A | |
dc.contributor.author | Tsubota, S | |
dc.contributor.author |
Beck, D https://orcid.org/0000-0002-9908-4341 |
|
dc.contributor.author | Kadomatsu, K | |
dc.contributor.author | Beckers, A | |
dc.contributor.author | Durink, K | |
dc.contributor.author | De Preter, K | |
dc.contributor.author | Speleman, F | |
dc.contributor.author | Haber, M | |
dc.contributor.author | Norris, MD | |
dc.contributor.author | Swarbrick, A | |
dc.contributor.author | Cheung, BB | |
dc.contributor.author | Marshall, GM | |
dc.contributor.author | Carter, DR | |
dc.date.accessioned | 2024-04-05T03:12:46Z | |
dc.date.available | 2023-10-19 | |
dc.date.available | 2024-04-05T03:12:46Z | |
dc.date.issued | 2023-10-25 | |
dc.identifier.citation | Int J Mol Sci, 2023, 24, (21), pp. 15571 | |
dc.identifier.issn | 1422-0067 | |
dc.identifier.issn | 1422-0067 | |
dc.identifier.uri | http://hdl.handle.net/10453/177496 | |
dc.description.abstract | MYCN amplification occurs in approximately 20-30% of neuroblastoma patients and correlates with poor prognosis. The TH-MYCN transgenic mouse model mimics the development of human high-risk neuroblastoma and provides strong evidence for the oncogenic function of MYCN. In this study, we identified mitotic dysregulation as a hallmark of tumor initiation in the pre-cancerous ganglia from TH-MYCN mice that persists through tumor progression. Single-cell quantitative-PCR of coeliac ganglia from 10-day-old TH-MYCN mice revealed overexpression of mitotic genes in a subpopulation of premalignant neuroblasts at a level similar to single cells derived from established tumors. Prophylactic treatment using antimitotic agents barasertib and vincristine significantly delayed the onset of tumor formation, reduced pre-malignant neuroblast hyperplasia, and prolonged survival in TH-MYCN mice. Analysis of human neuroblastoma tumor cohorts showed a strong correlation between dysregulated mitosis and features of MYCN amplification, such as MYC(N) transcriptional activity, poor overall survival, and other clinical predictors of aggressive disease. To explore the therapeutic potential of targeting mitotic dysregulation, we showed that genetic and chemical inhibition of mitosis led to selective cell death in neuroblastoma cell lines with MYCN over-expression. Moreover, combination therapy with antimitotic compounds and BCL2 inhibitors exploited mitotic stress induced by antimitotics and was synergistically toxic to neuroblastoma cell lines. These results collectively suggest that mitotic dysregulation is a key component of tumorigenesis in early neuroblasts, which can be inhibited by the combination of antimitotic compounds and pro-apoptotic compounds in MYCN-driven neuroblastoma. | |
dc.format | Electronic | |
dc.language | eng | |
dc.publisher | MDPI | |
dc.relation | Cancer Institute NSW2017/ECF011 | |
dc.relation.ispartof | Int J Mol Sci | |
dc.relation.isbasedon | 10.3390/ijms242115571 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 0399 Other Chemical Sciences, 0604 Genetics, 0699 Other Biological Sciences | |
dc.subject.classification | Chemical Physics | |
dc.subject.classification | 3101 Biochemistry and cell biology | |
dc.subject.classification | 3107 Microbiology | |
dc.subject.classification | 3404 Medicinal and biomolecular chemistry | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Animals | |
dc.subject.mesh | N-Myc Proto-Oncogene Protein | |
dc.subject.mesh | Antimitotic Agents | |
dc.subject.mesh | Cell Line, Tumor | |
dc.subject.mesh | Mice, Transgenic | |
dc.subject.mesh | Neuroblastoma | |
dc.subject.mesh | Cell Transformation, Neoplastic | |
dc.subject.mesh | Gene Expression Regulation, Neoplastic | |
dc.subject.mesh | Cell Line, Tumor | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Mice, Transgenic | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Neuroblastoma | |
dc.subject.mesh | Cell Transformation, Neoplastic | |
dc.subject.mesh | Gene Expression Regulation, Neoplastic | |
dc.subject.mesh | Antimitotic Agents | |
dc.subject.mesh | N-Myc Proto-Oncogene Protein | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Animals | |
dc.subject.mesh | N-Myc Proto-Oncogene Protein | |
dc.subject.mesh | Antimitotic Agents | |
dc.subject.mesh | Cell Line, Tumor | |
dc.subject.mesh | Mice, Transgenic | |
dc.subject.mesh | Neuroblastoma | |
dc.subject.mesh | Cell Transformation, Neoplastic | |
dc.subject.mesh | Gene Expression Regulation, Neoplastic | |
dc.title | Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma. | |
dc.type | Journal Article | |
utslib.citation.volume | 24 | |
utslib.location.activity | Switzerland | |
utslib.for | 0399 Other Chemical Sciences | |
utslib.for | 0604 Genetics | |
utslib.for | 0699 Other Biological Sciences | |
pubs.organisational-group | University of Technology Sydney | |
pubs.organisational-group | University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | University of Technology Sydney/Strength - CHT - Health Technologies | |
pubs.organisational-group | University of Technology Sydney/Strength - AAI - Advanced Analytics Institute Research Centre | |
pubs.organisational-group | University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2024-04-05T03:12:29Z | |
pubs.issue | 21 | |
pubs.publication-status | Published online | |
pubs.volume | 24 | |
utslib.citation.issue | 21 |
Abstract:
MYCN amplification occurs in approximately 20-30% of neuroblastoma patients and correlates with poor prognosis. The TH-MYCN transgenic mouse model mimics the development of human high-risk neuroblastoma and provides strong evidence for the oncogenic function of MYCN. In this study, we identified mitotic dysregulation as a hallmark of tumor initiation in the pre-cancerous ganglia from TH-MYCN mice that persists through tumor progression. Single-cell quantitative-PCR of coeliac ganglia from 10-day-old TH-MYCN mice revealed overexpression of mitotic genes in a subpopulation of premalignant neuroblasts at a level similar to single cells derived from established tumors. Prophylactic treatment using antimitotic agents barasertib and vincristine significantly delayed the onset of tumor formation, reduced pre-malignant neuroblast hyperplasia, and prolonged survival in TH-MYCN mice. Analysis of human neuroblastoma tumor cohorts showed a strong correlation between dysregulated mitosis and features of MYCN amplification, such as MYC(N) transcriptional activity, poor overall survival, and other clinical predictors of aggressive disease. To explore the therapeutic potential of targeting mitotic dysregulation, we showed that genetic and chemical inhibition of mitosis led to selective cell death in neuroblastoma cell lines with MYCN over-expression. Moreover, combination therapy with antimitotic compounds and BCL2 inhibitors exploited mitotic stress induced by antimitotics and was synergistically toxic to neuroblastoma cell lines. These results collectively suggest that mitotic dysregulation is a key component of tumorigenesis in early neuroblasts, which can be inhibited by the combination of antimitotic compounds and pro-apoptotic compounds in MYCN-driven neuroblastoma.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph